Topic 20 — Malaria: Parasite, Clinical Disease, Prevention and Antimalarial Pharmacotherapy

A rapid connected view of parasite biology, disease mechanism, diagnosis, drug action, prevention and family-practice decision-making.

1. THE TOPIC IN ONE CONNECTED FLOW

Malaria becomes easy to integrate when the parasite life cycle is linked directly to the patient’s symptoms, laboratory diagnosis, treatment targets and prevention. The same sequence explains why liver-stage drugs prevent relapse, why blood-stage drugs control acute attacks and why vector control remains essential at population level.

Infective Bite

Female Anopheles injects sporozoites

→

Liver Stage

Hepatic schizonts form; P. vivax/P. ovale may leave hypnozoites

→

Blood Stage

Merozoites invade erythrocytes and multiply

→

Clinical Disease

RBC rupture + cytokine release → fever, chills, anemia, splenomegaly

→

Severe Falciparum Disease

Sequestration in microvessels → organ dysfunction

→

Diagnosis

Thick film detects parasites; thin film helps identify species and parasitemia

→

Treatment & Prevention

Blood-stage drugs treat attacks; liver-stage therapy prevents relapse; vector control interrupts transmission

2. KEY CLINICAL CONNECTIONS

Falciparum Severity

Infected erythrocytes adhere to vascular endothelium → microvascular sequestration → impaired tissue perfusion → confusion, renal dysfunction, respiratory compromise or shock.

Drug Stage Determines Clinical Use

Blood schizonticides → clear erythrocytic parasites → control acute clinical attacks.

Primaquine → eliminates hepatic hypnozoites → prevents relapse in P. vivax and P. ovale, but G6PD deficiency creates a major hemolysis risk.

Clinical Suspicion Must Lead to Parasitological Testing

Fever + relevant exposure → test for malaria → thick film improves detection while thin film helps species identification. A single negative film does not necessarily exclude malaria when suspicion remains high.

Public Health Connection

Rainfall, standing water and vector density → increased transmission → higher community burden → bed nets, indoor residual spraying, early diagnosis and effective treatment reduce further spread.

3. AIM HIGH-YIELD INTEGRATION REVIEW

⭐ Sporozoite → liver → merozoite → erythrocyte: this sequence connects mosquito transmission with the stage that produces clinical disease.

⭐ Hypnozoites → relapse: dormant hepatic forms occur in P. vivax and P. ovale, so blood-stage therapy alone does not provide radical cure.

RBC rupture → fever and anemia: parasite multiplication damages erythrocytes, while cytokine release produces febrile symptoms and splenic clearance contributes to anemia.

⭐ Falciparum sequestration → severe disease: microvascular obstruction explains neurological, renal, respiratory and circulatory red flags requiring urgent referral.

Chloroquine → impaired heme detoxification → parasite death: its extensive tissue distribution explains its very large apparent volume of distribution and prolonged persistence.

Pyrimethamine → DHFR inhibition → reduced tetrahydrofolate: parasite nucleotide synthesis falls, while excessive antifolate activity can also produce marrow toxicity.

⭐ Primaquine → liver-stage eradication → relapse prevention: the same oxidative activity that makes it useful also creates dangerous hemolysis in G6PD deficiency.

Vector risk + human reservoir → ongoing transmission: personal protection, vector control, surveillance, diagnosis and effective treatment must work together to reduce malaria burden.

AIM Exam Trap:
Suppressive prophylaxis mainly prevents clinical attacks by acting on blood stages, whereas causal prophylaxis targets pre-erythrocytic liver forms; terminal prophylaxis and radical cure address persisting hepatic forms in relapsing malaria.

Topic 20 — Malaria: Parasite, Clinical Disease, Prevention and Antimalarial Pharmacotherapy

1. THE TOPIC IN ONE CONNECTED FLOW

2. KEY CLINICAL CONNECTIONS

3. AIM HIGH-YIELD INTEGRATION REVIEW

Install AIM App